InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the full record of transactions filed by Mottola Frank, VP Senior. Director active across 1 company, notably Supernus Pharmaceuticals, INC.. Aggregated, 21 reports have been published. Breakdown: 0 buy · 1 sell. Total volume traded: €160k. History available since 16 February 2023. The latest transaction was filed on 12 August 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Mottola Frank
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报21 总计
1,650 股0Common StockSEC:0001804567-26-000014:0
797 股@ US$46.57Common StockSEC:0001804567-26-000014:1
3,750 股0Common StockSEC:0001804567-26-000010:0
1,875 股0Common StockSEC:0001804567-26-000006:0
1,125 股0Common StockSEC:0001804567-26-000004:0
5,000 股@ US$39.400.0059% mcap50.0% 占其流量Common StockSEC:0001628280-25-058506:0
5,000 股@ US$39.4020.8% 占其流量Common StockSEC:0001804567-25-000006:0
14,000 股@ US$12.9824.4% 占其流量Common StockSEC:0001804567-25-000004:0
2,625 股0Common StockSEC:0001628280-25-011325:0
337 股@ US$33.051.6% 占其流量Common StockSEC:0001628280-25-010472:0
2,010 股0Common StockSEC:0001628280-25-008262:0
1,125 股0Common StockSEC:0001628280-25-007528:0
15,000 股@ US$9.1319.6% 占其流量Common StockSEC:0001628280-24-046668:0
990 股0Common StockSEC:0001104659-24-029434:0
1,875 股0Common StockSEC:0001104659-24-028276:0
750 股0Common StockSEC:0001104659-24-027571:0
2,000 股@ US$9.242.6% 占其流量Common StockSEC:0001104659-23-119162:0
750 股0Common StockSEC:0001104659-23-044665:0
4,780 股@ US$35.98824.6% 占其流量Common StockSEC:0001104659-23-033366:0
750 股0Common StockSEC:0001104659-23-025368:0
1,500 股0Common StockSEC:0001104659-23-023877:0
21 条申报中的 21 条
About Mottola Frank
Mottola Frank is VP Senior and SVP, Chief Tech. Ops. Officer at Supernus Pharmaceuticals, INC. He has 19 filings in total, and in the sampled recent filings, sales total 160394 EUR over the period from 2023-02-21 to 2026-03-10, with the transaction nature listed as option exercise.
